Nevertheless, the presence of breast cancers within the BRCA-proficient group that demonstrated signature 3 activity suggests that there may be samples in which have hitherto defects not identified in BRCA1 or BRCA2 or defects in other homologous recombination repair genes such as that of PALB2 and RAD51C [26]. This evidence concerns the gene RAD51C and breast carcinoma.